Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKLINASDAQ:KRMDNASDAQ:LUNGNASDAQ:PDEX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKLIAkili$0.43$0.43$0.19▼$1.25$34.01M1.722.20 million shsN/AKRMDKORU Medical Systems$2.88+1.4%$2.63$1.86▼$5.05$132.89M0.39133,691 shs66,688 shsLUNGPulmonx$3.07-3.5%$4.49$2.83▼$9.37$123.59M0.52312,107 shs87,245 shsPDEXPro-Dex$41.29-3.5%$51.95$16.84▼$70.26$134.65M0.3731,081 shs16,431 shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKLIAkili0.00%0.00%0.00%0.00%+2.86%KRMDKORU Medical Systems+1.79%-2.41%-0.35%-11.80%+33.96%LUNGPulmonx+1.60%+2.91%-15.65%-61.17%-53.91%PDEXPro-Dex+9.02%-3.02%-6.72%+24.54%+119.05%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKLIAkiliN/AN/AN/AN/AN/AN/AN/AN/AKRMDKORU Medical Systems3.6471 of 5 stars3.55.00.00.03.72.50.6LUNGPulmonx3.1309 of 5 stars4.32.00.00.02.12.50.6PDEXPro-Dex3.2175 of 5 stars3.52.00.00.02.32.51.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKLIAkili 0.00N/AN/AN/AKRMDKORU Medical Systems 3.00Buy$4.5056.25% UpsideLUNGPulmonx 2.63Moderate Buy$11.53275.41% UpsidePDEXPro-Dex 3.00Buy$56.0035.63% UpsideCurrent Analyst Ratings BreakdownLatest AKLI, KRMD, PDEX, and LUNG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2025PDEXPro-DexAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$54.00 ➝ $56.005/22/2025LUNGPulmonxCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$6.50 ➝ $4.155/8/2025KRMDKORU Medical SystemsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$4.50 ➝ $3.505/1/2025LUNGPulmonxCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$16.00 ➝ $15.005/1/2025LUNGPulmonxPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$10.00 ➝ $9.005/1/2025LUNGPulmonxD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$17.00 ➝ $17.003/13/2025KRMDKORU Medical SystemsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy3/10/2025LUNGPulmonxJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy3/10/2025LUNGPulmonxMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageEqual Weight ➝ Equal Weight3/10/2025LUNGPulmonxCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral ➝ Buy3/10/2025LUNGPulmonxD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy ➝ Buy$17.00 ➝ $17.00(Data available from 6/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKLIAkili$1.95M17.46N/AN/A$0.75 per share0.58KRMDKORU Medical Systems$35.08M3.79N/AN/A$0.45 per share6.40LUNGPulmonx$87.47M1.41N/AN/A$3.09 per share0.99PDEXPro-Dex$64.12M2.10$1.19 per share34.81$9.76 per share4.23Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKLIAkili-$59.49M-$0.61N/AN/AN/A-2,492.04%-79.93%-59.16%N/AKRMDKORU Medical Systems-$13.74M-$0.11N/AN/AN/A-37.42%-24.60%-16.87%8/6/2025 (Estimated)LUNGPulmonx-$60.84M-$1.44N/AN/AN/A-67.31%-55.36%-33.53%7/30/2025 (Estimated)PDEXPro-Dex$2.13M$2.8020.5420.04N/A11.06%21.68%12.40%N/ALatest AKLI, KRMD, PDEX, and LUNG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2025Q1 2025KRMDKORU Medical Systems-$0.02-$0.03-$0.01-$0.03$8.86 million$9.64 million5/7/2025Q1 2025LUNGPulmonx-$0.37-$0.36+$0.01-$0.36$22.03 million$22.54 million5/1/2025Q3 2025PDEXPro-Dex$0.47$0.98+$0.51$0.98$17.70 million$17.41 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKLIAkiliN/AN/AN/AN/AN/AKRMDKORU Medical SystemsN/AN/AN/AN/AN/ALUNGPulmonxN/AN/AN/AN/AN/APDEXPro-DexN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKLIAkili0.085.805.80KRMDKORU Medical Systems0.012.992.37LUNGPulmonx0.407.706.77PDEXPro-Dex0.332.581.44Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKLIAkili53.12%KRMDKORU Medical Systems58.60%LUNGPulmonx91.04%PDEXPro-Dex15.28%Insider OwnershipCompanyInsider OwnershipAKLIAkili10.10%KRMDKORU Medical Systems20.60%LUNGPulmonx6.80%PDEXPro-Dex47.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKLIAkili13078.73 million70.78 millionOptionableKRMDKORU Medical Systems8046.14 million34.10 millionOptionableLUNGPulmonx25040.26 million37.24 millionOptionablePDEXPro-Dex1403.26 million1.71 millionNot OptionableAKLI, KRMD, PDEX, and LUNG HeadlinesRecent News About These CompaniesPro-Dex (NASDAQ:PDEX) Price Target Raised to $56.00 at Ascendiant Capital MarketsMay 28, 2025 | marketbeat.comAscendiant Capital Markets Issues Positive Forecast for Pro-Dex (NASDAQ:PDEX) Stock PriceMay 28, 2025 | americanbankingnews.comOMERS ADMINISTRATION Corp Takes Position in Pro-Dex, Inc. (NASDAQ:PDEX)May 22, 2025 | marketbeat.comAre Pro-Dex, Inc.'s (NASDAQ:PDEX) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?May 20, 2025 | finance.yahoo.comPro-Dex (NASDAQ:PDEX) Share Price Crosses Below Two Hundred Day Moving Average - Should You Sell?May 15, 2025 | marketbeat.com9,260 Shares in Pro-Dex, Inc. (NASDAQ:PDEX) Bought by Marshall Wace LLPMay 6, 2025 | marketbeat.comPro-Dex: Crash After Strong Earnings Leads To A Buying OpportunityMay 5, 2025 | seekingalpha.comHere's Why Pro-Dex (NASDAQ:PDEX) Has Caught The Eye Of InvestorsMay 4, 2025 | uk.finance.yahoo.com683 Capital Management LLC Makes New $739,000 Investment in Pro-Dex, Inc. (NASDAQ:PDEX)May 4, 2025 | marketbeat.comPro-Dex, Inc. (PDEX) Q3 Earnings Surpass EstimatesMay 1, 2025 | zacks.comPro-Dex, Inc. Announces Fiscal 2025 Third Quarter and Nine-Month ResultsMay 1, 2025 | accessnewswire.comProDex (PDEX) Moves 5.1% Higher: Will This Strength Last?April 25, 2025 | zacks.comTake the Zacks Approach to Beat the Markets: Pro-Dex, Brookdale Senior Living, Coca-Cola in FocusApril 21, 2025 | zacks.comProDex (PDEX) Surges 7.4%: Is This an Indication of Further Gains?April 3, 2025 | zacks.comPro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot Sells 842 SharesApril 2, 2025 | insidertrades.comPro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot Sells 836 SharesApril 1, 2025 | insidertrades.comInsider Selling: Pro-Dex, Inc. (NASDAQ:PDEX) Director Sells 3,096 Shares of StockMarch 28, 2025 | insidertrades.comInsider Selling: Pro-Dex, Inc. (NASDAQ:PDEX) Director Sells 5,151 Shares of StockMarch 18, 2025 | insidertrades.comWith 38% ownership in Pro-Dex, Inc. (NASDAQ:PDEX), hedge funds investors have a lot riding on the businessMarch 11, 2025 | finance.yahoo.comProDex (PDEX) Upgraded to Strong Buy: Here's What You Should KnowFebruary 28, 2025 | zacks.com(PDEX) Investment ReportFebruary 8, 2025 | news.stocktradersdaily.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAKLI, KRMD, PDEX, and LUNG Company DescriptionsAkili NASDAQ:AKLIAkili, Inc., a digital medicine company, develops cognitive treatments through game-changing technologies. The company provides EndeavorRx, a computer-based testing for cognitive dysfunction across several neurology and psychiatry indications, including attention-deficit hyperactivity disorder, depressive disorder, autism spectrum disorder, multiple sclerosis, and other neuroinflammatory diseases. It also offers selective stimulus management engine mechanism to activate the fronto-parietal cortex area in the brain; body brain trainer for attention, impulsivity, working memory, and goal management; and spatial navigation engine for spatial navigation, memory, and planning and organization. The company was founded in 2011 and is headquartered in Boston, Massachusetts.KORU Medical Systems NASDAQ:KRMD$2.88 +0.04 (+1.41%) As of 01:33 PM EasternKORU Medical Systems, Inc. develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products. The company was incorporated in 1980 and is based in Mahwah, New Jersey.Pulmonx NASDAQ:LUNG$3.07 -0.11 (-3.46%) As of 01:30 PM EasternPulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.Pro-Dex NASDAQ:PDEX$41.29 -1.50 (-3.51%) As of 01:31 PM EasternPro-Dex, Inc. designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets. It also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. The company's products are used in hospitals, medical engineering labs, scientific research facilities, and high-tech manufacturing operations. Pro-Dex, Inc. was founded in 1978 and is headquartered in Irvine, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Guidewire Rockets Higher: A Move Above $300 Is Probable TSMC Joins NVIDIA in UAE Push, Fueling Growth Outlook Constellation Energy and Meta Strike Nuclear Deal, Shares Whipsaw Archer's Midnight Air Taxi Soars, But Stock Doesn’t Budge Analog Devices' Cyclical Recovery Story Has Just Begun Microsoft Stock Near Peak, Pullback Seen as Opportunity 3 Reasons Amazon Could Be the Best Tech Performer in June 3 Tech Stocks Insiders Are Buying: Speculative Plays for June Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
